In uncontrolled T2DM treated with a basal-bolus insulin regimen, weekly icodec was noninferior to daily glargine for HbA<sub>1c</sub> at 26 wk.
rct · Level II
Where this comes from
- Record sourced from PubMed, PMID 37523705.
- Also identified by DOI 10.7326/J23-0058.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Mathieu C, Ásbjörnsdóttir B, Bajaj HS, et al. <b>Switching to once-weekly insulin icodec versus once-daily insulin glargine U100 in individuals with basal-bolus insulin-treated type 2 diabetes (ONWARDS 4): a phase 3a, randomised, open-label, multicentre, treat-to-target, non-inferiority trial.</b> Lancet. 2023;401:1929-1940. 37156252.
Medical subject headings
- Diabetes Mellitus, Type 2